In the context of brain metastases, Miao et al. investigated clinicogenomic outcomes in ALK-positive NSCLC patients treated with alectinib, finding that SMARCA4-mutated patients with brain metastases were the only group with co-mutations to exhibit statistically worse outcomes in a multivariate analysis (HR: 8.76; p = 0.009) [25]. This evidence concerns the gene ALK and non-small cell lung carcinoma.